Table 2.
Baseline characteristics of the study participants, mean ± SD or n (%).
| Clopidogrel (n = 223) | Ticagrelor (n = 214) | P value | |
|---|---|---|---|
| Age, years | 63 ± 10 | 62 ± 9 | 0.502 |
| Body mass index (kg/m2) | 27.2 ± 4.1 | 27.3 ± 4.3 | 0.727 |
| Male, n (%) | 153 (68.6%) | 130 (60.7%) | 0.085 |
| Hypertension, n (%) | 141 (63.2%) | 122 (57%) | 0.184 |
| Diabetes mellitus, n (%) | 75 (33.6%) | 64 (29.9%) | 0.403 |
| Smoker, n (%) | 51 (22.9%) | 56 (26.2%) | 0.423 |
| Dyslipidemia, n (%) | 83 (37.2%) | 107 (50%) | 0.007 |
| COPD, n (%) | 9 (4%) | 16 (7.5%) | 0.150 |
| Asthma, n (%) | 5 (2.2%) | 12 (5.6%) | 0.085 |
| HFrEF, n (%) | 21 (9.4%) | 7 (3.3%) | 0.008 |
| Atrial fibrillation, n (%) | 4 (1.8%) | 0 (0%) | 0.124 |
| Anemia, n (%) | 7 (3.1%) | 14 (6.5%) | 0.118 |
COPD: chronic obstructive pulmonary disease; HFrEF: heart failure with reduced ejection fraction.